Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Barinthus Biotherapeutics plc - American Depositary Shares (NQ: BRNS ) 1.250 -0.050 (-3.85%) Streaming Delayed Price Updated: 1:34 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Barinthus Biotherapeutics plc - American Depositary Shares BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024 August 08, 2024 BRNS stock results show that Barinthus Biotherapeutics missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results August 08, 2024 From Barinthus Biotherapeutics Via GlobeNewswire Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors August 01, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket June 21, 2024 Via Benzinga Barinthus Biotherapeutics: Q4 Earnings Insights March 20, 2024 Via Benzinga Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections June 12, 2024 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B June 06, 2024 From Barinthus Biotherapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session June 05, 2024 Via Benzinga Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024 May 22, 2024 From Barinthus Biotherapeutics Via GlobeNewswire BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024 May 13, 2024 BRNS stock results show that Barinthus Biotherapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments May 13, 2024 From Barinthus Biotherapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session May 01, 2024 Via Benzinga Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer May 01, 2024 Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseases From Barinthus Biotherapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Intraday Session April 30, 2024 Via Benzinga Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives April 19, 2024 Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted,... Via Benzinga Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections April 18, 2024 From Barinthus Biotherapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session April 04, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session April 03, 2024 Via Benzinga BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q4 2023 March 20, 2024 BRNS stock results show that Barinthus Biotherapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments March 20, 2024 From Barinthus Biotherapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Pre-Market Session February 19, 2024 Via Benzinga Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones January 05, 2024 From Barinthus Biotherapeutics Via GlobeNewswire New partnership aims to advance vaccine against MERS coronavirus December 21, 2023 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD November 09, 2023 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments November 09, 2023 From Barinthus Biotherapeutics Via GlobeNewswire Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting® November 09, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.